Evidence map›Paper›PMID 40325170›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Biochemical and structural response in patients with tall cell papillary thyroid cancer: a dual centre retrospective study : Early Recurrence in Tall Cell PTC.

Louis Britten-Jones, Spinder Samra, David Goltsman, Gideon Sandler, Matti L Gild, Christian M Girgis

Abstract readMulticenter Study
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Aggressive follicular cell derived thyroid carcinoma: what do you need from the pathologist.Virchows Archiv : an international journal of pathology · 2026
    Review
  2. Letter to ''Biochemical and structural response in patients with tall cell papillary thyroid cancer''.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Louis Britten-JonesUniversity of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0009-0004-8578-0946
Spinder SamraUniversity of Sydney, Sydney, NSW, Australia.
David GoltsmanWestmead Hospital, Sydney, NSW, Australia.
Gideon SandlerWestmead Hospital, Sydney, NSW, Australia.
Matti L GildUniversity of Sydney, Sydney, NSW, Australia. matti.gild@sydney.edu.au.
Christian M GirgisUniversity of Sydney, Sydney, NSW, Australia. Christian.girgis@sydney.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTall cell papillary thyroid cancer (tcPTC) is traditionally considered to be an aggressive subtype of differentiated thyroid cancer, although its independent prognostic value is unclear. To investigate the independent prognostic value of tall cell morphology a tcPTC cohort was compared with a classical PTC (cPTC) cohort.

methodsA retrospective longitudinal study was performed using a cohort of tcPTC patients treated at Royal North Shore Hospital and Westmead Hospital in Sydney, Australia, and a cohort of cPTC patients treated at Westmead Hospital. Clinicopathological tumour characteristics and treatment pathways were analysed. Thyroglobulin and thyroglobulin antibody levels and further neck surgeries in the two years post thyroidectomy were used as a surrogate marker for early disease recurrence.

resultsPresentation and treatment were analysed for 51 tcPTC patients and a comparator group of 365 cPTC patients. On univariate analysis, tcPTC was found to present at an older age (53.6 years v 46.4 years, p < 0.01), with greater rates of positive surgical margins (31.37% v 16.44%, p < 0.05), and greater rates of microscopic (47.06% v 22.74%, p < 0.001) and gross extrathyroidal extension (15.69% v 6.30%, p < 0.05). Longitudinal analysis was conducted for 236 patients (n = 24 for tcPTC, n = 212 for cPTC). Multivariate analysis found no difference in the odds of developing early recurrence between the tcPTC cohort and the cPTC cohort (OR = 0.65, p > 0.1).

conclusiontcPTC is associated with more aggressive features compared with cPTC. Tall cell morphology was not found to be an independent predictor of early recurrence.

Indexed as

Neoplasm Recurrence, LocalThyroid Cancer, PapillaryThyroid NeoplasmsAdultAgedFemaleHumansLongitudinal StudiesMaleMiddle AgedPrognosisRetrospective StudiesThyroglobulinThyroidectomyThyroglobulinEarly recurrencePapillary thyroid cancerPrognosisRetrospective studiesRisk assessmentTall cell subtype

Identifiers

PMID40325170
PMCPMC12399698

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.